Bladder cancer

被引:34
作者
Borden, LS [1 ]
Clark, PE [1 ]
Hall, MC [1 ]
机构
[1] Wake Forest Univ, Sch Med, Dept Urol, Winston Salem, NC 27157 USA
关键词
bladder cancer; review; transitional cell carcinoma; urothelial carcinoma;
D O I
10.1097/01.cco.0000156985.47984.9e
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review This article reviews the recent literature concerning important issues in the management of patients with bladder cancer. A brief overview of all aspects of bladder cancer including the etiology, diagnosis, and treatment are discussed with a focus on recent advances. Recent findings Bladder cancer is a significant cause of morbidity and mortality. The treatment for bladder cancer should be based on individual patient risk assessment and should include a multidisciplinary approach. In patients with superficial bladder cancer, research has focused on improving and optimizing intravesical therapy to reduce tumor recurrence and progression as well as on methods to better select the most appropriate treatment for patients with high-risk features, The important prognostic and therapeutic role of lymphadenectomy during radical cystectomy has become apparent and recent work has attempted to better define what should be considered the standard for lymph node dissection. Finally, in an attempt to improve survival, advances have been made using systemic chemotherapy in both the perioperative settings as well as for treatment of metastatic bladder cancer. Summary Research continues to improve our understanding of bladder cancer. This ongoing investigation is currently being translated to the bedside with refinements in the diagnosis and treatment of patients with bladder cancer.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 52 条
[1]   Nodal involvement in bladder cancer cases treated with radical cystectomy: Incidence and prognosis [J].
Abdel-Latif, M ;
Abol-Enein, H ;
El-Baz, M ;
Ghoneim, MA .
JOURNAL OF UROLOGY, 2004, 172 (01) :85-89
[2]  
Abol-Enein H, 2003, LANCET, V361, P1927
[3]   Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: Long term results [J].
Bamias, A ;
Deliveliotis, C ;
Karayiannis, A ;
Varkarakis, I ;
Zervas, I ;
Pantazopoulos, D ;
Gika, D ;
Dimopoulos, MA .
EUROPEAN UROLOGY, 2004, 46 (03) :344-350
[4]   Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [J].
Bamias, A ;
Aravantinos, G ;
Deliveliotis, C ;
Bafaloukos, D ;
Kalofonos, C ;
Xiros, N ;
Zervas, A ;
Mitropoulos, D ;
Samantas, E ;
Pectasides, D ;
Papakostas, P ;
Gika, D ;
Kourousis, C ;
Koutras, A ;
Papadimitriou, C ;
Bamias, C ;
Kosmidis, P ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :220-228
[5]   Prospectively packaged lymph node dissections with radical cystectomy: Evaluation of node count variability and node mapping [J].
Bochner, BH ;
Cho, D ;
Herr, HW ;
Donat, M ;
Kattan, MW ;
Dalbagni, G .
JOURNAL OF UROLOGY, 2004, 172 (04) :1286-1290
[6]  
Böhle A, 2004, UROLOGY, V63, P682, DOI 10.1016/j.urology.2003.11.049
[7]   Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].
Böhle, A ;
Jocham, D ;
Bock, PR .
JOURNAL OF UROLOGY, 2003, 169 (01) :90-95
[8]   Does extended lymphadenectomy increase the morbidity of radical cystectomy? [J].
Brössner, C ;
Pycha, A ;
Toth, A ;
Mian, C ;
Kuber, W .
BJU INTERNATIONAL, 2004, 93 (01) :64-66
[9]  
Calabro Fabio, 2002, Curr Opin Urol, V12, P441, DOI 10.1097/00042307-200209000-00013
[10]   Impact of a second transurethral resection on the staging of T1 bladder cancer [J].
Dalbagni, G ;
Herr, HW ;
Reuter, VE .
UROLOGY, 2002, 60 (05) :822-824